Tests an online lifestyle program for adults with type 2 diabetes
Tests an online lifestyle program in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: DiaMester Pilot RCT: E-health Lifestyle Program for Type 2 Diabetes
Key facts
- Where
- Oslo, NorwaySee the site
Where in Norway
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT07361640
- Record updated
- 23 January 2026
- Original description
This registration covers a pilot for a 3-armed parallel-group randomized controlled trial (RCT) that will evaluate the efficacy of DiaMester, a Norwegian e-health programme designed to improve self-management and induce clinically meaningful weight loss, and thereby potential remission in adults with type 2 diabetes (T2D).Read full original descriptionShow less
DiaMester: E-health Lifestyle Program for Improved Self-management and Remission of Type 2 Diabetes - a Pilot RCT
This registration covers a pilot for a 3-armed parallel-group randomized controlled trial (RCT) that will evaluate the efficacy of DiaMester, a Norwegian e-health programme designed to improve self-management and induce clinically meaningful weight loss, and thereby potential remission in adults with type 2 diabetes (T2D).
Inclusion: Written informed consent; Men and women aged ≥ 18 years; Type 2 diabetes of duration 0-6 years (diagnosis based on 2 recorded diagnostic-level tests, HbA1c and/or blood glucose); HbA1c ≥ 48 mmol/mol at the last routine clinical check, within last 12 months if on diet alone; HbA1c ≥ 43 mmol/mol if on treatment with oral hypoglycaemic agents or GLP-1 RA treatment; Body Mass Index (BMI) >27 kg/m2; Stable body weight during the last 6 months with or without the use of weight-reducing drugs; Self-reported desire to lose weight; Owns a smartphone.
Exclusion: > 5% weight change or started treatment with weight reducing drugs* within the last 6 months. *orlistat (Xenical), bupropion-naltrekson (Mysimba), fenteramin-topiramat (Qsimba), semaglutid (Wegovy, Ozempic), tirzepatid (Mounjaro), liraglutid (Saxenda, Victoza), dulaglutid (Truicity); Myocardial infarction within previous 6 months; Substance abuse (drugs, alcohol); Patients who have required hospitalization for depression or are on antipsychotic drugs; Known cancer; Severe heart failure defined as equivalent to the New York Heart Association grade 3 (NYHA); Diagnosed eating disorders or suspected ED based on screening questionnaire; Recent routine HbA1c ≥108 mmol/mol; Recent eGFR <30 ml/min/1.73 m\^2; Current insulin use; Pregnancy/considering pregnancy or exclusively breastfeeding; Learning difficulties or unable to understand, speak and read Norwegian or English; People currently participating in another clinical research trial.